why biotechs need to worry about generics, too, page-5

Big pharma gunna have to do the cost benefit analysis... does the benefit of best in class safety, cost savings in storage, transport, etc and product differentiation vs generics exceed the cost premium paid for unifills.

Would be nice if our delivery device actually extended patent lifes as well but I doubt that very much.

Still, product differentiation is a key buzzword in the fight against generics... its all been said before anyhoo....